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http://dx.doi.org/10.1016/j.jfma.201Virus-associated human cancers may exhibit two characteristic histopathologic features: (1)
the inflammation-rich background as observed in EpsteineBarr virus-associated Hodgkin lym-
phoma (HL) and nasopharyngeal carcinoma (NPC); and (2) the characteristic nuclear
morphology such as the Reed-Sternberg cells in HL. Besides, the hepatocytes of chronic hep-
atitis B virus (HBV) infection frequently exhibit characteristic ground glass hepatocytes, a phe-
nomenon associated with endoplasmic reticulum stress response induced by the overloaded or
malfolded HBV surface antigens. In this review, we explore specifically the pathogenesis of Ep-
steineBarr virus-associated HL and NPC, and HBV-associated hepatocellular carcinoma based
on the observed histopathologic features. We propose that the retention of viral proteins in-
duces inflammation, endoplasmic reticulum stress, and genomic instability in HL, NPC, and he-
patocellular carcinoma, whereby the viral oncoproteins may play additional transactivational
roles to induce host genes for transformation, invasion, and metastasis. Therapeutic implica-
tions based on the pathogenesis of virus-associated cancers are discussed.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.ave no conflicts of interest relevant to this article.
titute of Infectious Diseases and Vaccinology, National Health Research Institute Office, 367 Sheng-Li
w (I.-J. Su).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
3.09.001
582 K.-C. Chang et al.Introduction
ern Japan and Caribbean regions.22,23 In 1988, hepatitis CViruses can contribute to the development of several
human cancers and constitute 15e30% of human cancers
with geographic variation.1 Malignant lymphoma is one of
the human cancers most frequently associated with onco-
genic viruses.2,3 The African Burkitt’s lymphoma was first
identified to be associated with EpsteineBarr virus (EBV).4
Following Burkitt’s lymphoma, EBV was later found to be
associated with nasopharyngeal carcinoma (NPC),5 which is
prevalent in Hong Kong Cantonese.6,7 EBV was later found
to be associated with Hodgkin’s lymphoma (HL),8e10 post-
transplant lymphoma,11,12 and nasal type NK/T-cell lym-
phoma (Table 1).13,14 The ubiquitous EBV has been linked to
a spectrum of epithelial malignancies and smooth muscle
tumors in patients with acquired immunodeficiency syn-
drome.15 Other members of DNA viruses were later found to
be associated with human cancers. The hepatitis B virus
(HBV) was established to cause hepatocellular carcinoma
(HCC), representing the first example of human virus-
associated cancer controllable by vaccination.16 Human
papilloma viruses have been found to be associated with
cervical cancers and, recently, head and neck cancers, and
represent the second human cancer potentially control-
lable by vaccination.17,18 The vaccination program in the
control of virus-associated cancers represents a big success
in the battle against human cancers. In 1995, Kaposi’s
sarcoma herpes virus or human herpes virus 8 (HHV-8) was
found to cause Kaposi’s sarcoma in both human immuno-
deficiency virus-positive and -negative individuals.19e21
Besides DNA viruses, RNA viruses were later found to beTable 1 Viruses, associated human cancers, and relevant
oncoproteins.
Virus DNA
or RNA
Human cancers Oncoprotein
EBV DNA Burkitt lymphoma LMP, EBNA
Nasopharyngeal carcinoma
Lymphomas in
immunosuppressed hosts
Hodgkin lymphoma
NK/T-cell lymphoma
HBV DNA Hepatocellular carcinoma HBx, Pre-S
mutant
HCV RNA Hepatocellular carcinoma Core, NS3,
NS5A
HHV8 DNA Kaposi sarcoma vGPCR
HPV DNA Cervical carcinoma E6, E7
Head and neck carcinoma
HTLV-1 RNA Adult T-cell lymphoma/
leukemia
Tax
EBNA Z EBV nuclear antigen; EBV Z EpsteineBarr virus;
HBVZ hepatitis B virus; HBxZ HBV X protein; HCVZ hepatitis
C virus; HHV8 Z human herpes virus 8 (Kaposi sarcoma herpes
virusZ KSHV); HPVZ human papilloma virus; HTLV-1Z human
T-lymphotropic virus 1; LMP Z latent membrane protein;
NS Z nonstructural protein; Tax Z transactivator protein;
vGPCR Z viral G protein-coupled receptor.associated with adult T-cell leukemia/lymphoma in south-
virus was found to be the cause of non-A, non-B hepatitis
and closely related to the development of HCC.24
In the following sections, we will explore specifically the
pathogenesis of EBV-associated cancers and HBV-related
cancers, based on the observed histopathologic features.
The virus-associated human cancers may exhibit two char-
acteristic histopathologic features. The best known one is
the inflammation-rich background as observed in HL and
NPC or the so-called lymphoepithelioma.25 The second
histopathologic feature of virus-associated human cancers
is the characteristic nuclear morphology such as the
ReedeSternberg (RS) giant cells in HL.26 In addition to the
characteristic nuclear morphology, the hepatocytes of
chronic HBV infection frequently exhibit characteristic
glassy or so-called ground glass hepatocytes (GGHs), a
phenomenon associated with endoplasmic reticulum (ER)
stress response induced by the overloaded or malfolded
HBV surface antigens.27e29 Therefore, we focused the
pathogenesis on EBV-associated HL and NPC as well as HBV-
associated HCC in view of the characteristic pathologic
features.EBV and human cancers
EBV, also called human herpes virus 4 (HHV-4), is a member
of the herpes family and is one of the most common viruses
in man. In EBV-infected cells, based on the viral proteins
expressed, three latency transcription programs of EBV are
designated; growth program (latency III) with expression of
EBV nuclear antigens 1e6 (EBNA1e6) and latent membrane
antigens (LMP1, 2A and 2B); default program (latency II)
expressing EBNA1, LMP1 and LMP2A; and latency program
(latency I), with none or only expression of LMP2A.30 EBV
establishes successful life-long persistence in healthy car-
riers. Because many EBV proteins have oncogenic potential
and can be the targets recognized by the host immune
system, the virus stays peacefully with the host by
restraining viral replication and expression of latency pro-
gram of viral proteins.30 However, aberrant reactivation of
EBV from the latent phase into the replicative (lytic) phase
is frequently linked to the development or progression of
EBV-associated cancers, among which NPC is a typical
example. The EBV latent membrane protein 1 (LMP1) is a
well-documented oncoprotein generally detected in tissues
of HL and NPC but only rarely in normal tissues.31
HL
HL is the prototype of EBV-associated cancers that exhibit
two characteristic histopathologic features: an
inflammation-rich background, and the mysterious RS giant
cells (Fig. 1 inset). The malignant multinucleated RS cells, a
histologic hallmark of HL, occupy only a small proportion in
the tumors tissues.26 By contrast, the reactive inflamma-
tory cells constitute the majority of HL tumor mass. Like
local inflammation, many cytokines and chemokines are
detected in HL, including interleukin (IL)-5, IL-6, IL-10,
transforming growth factor-b, granulocyte-macrophage
colony-stimulating factor, and tumor necrosis factor-
b.32,33 Production of the inflammatory cytokines and
Figure 1 A unified model for EpsteineBarr virus (EBV)-associated Hodgkin lymphoma (HL) pathogenesis. (Inset) HL tumor cells
are multinucleated and embedded in an inflammatory background rich in lymphocytes, eosinophils and fibroblasts (400). EBV
latent membrane protein 1 (LMP1) activates the transcription factors, such as nuclear factor kB (NFkB) and signal transducer and
activator of transcription (STATs), and results in cytokine secretion and upregulation of growth factor receptors such as CD30,
CD40, and C-MET in HL cells. Furthermore, LMP1-induced endoplasmic reticulum (ER) stress promotes survival of tumor cells
through expression of ER stress survival proteins X-box-binding protein 1 (XBP-1) and glucose-regulated protein (GRP78) in HL
cells. LMP1 increases cytoplasmic localization of cyclin A, and the cytoplasmic cyclin A promotes the multinucleation of HL cells.
EBV nuclear antigen 1 (EBNA1) increases oxidative stress that enhances genomic instability.
Virus and cancer 583chemokines in HL results from constitutive activation of
some transcription factors, such as nuclear factor kB (NFkB)
and signal transducer and activator of transcription, in both
tumor cells and stromal cells.33e35 EBV-LMP1 is the viral
oncoprotein that activates the transcription factors
resulting in cytokine secretion and upregulation of growth
factor receptors such as CD30, CD40, and C-MET in RS cells
(Fig. 1).31 The inflammatory cells play an important role in
the pathobiology and tumorigenesis of HL.36 Current studies
have revealed a complex interplay of regulatory T cells,
CD8þ T cells, cytokines and chemokines, and tumor-
associated macrophages in the inflammatory milieu of
HL.32,37e40
NPC
The second EBV-associated cancer that exhibits a dense
inflammatory background and characteristic nuclear
morphology of tumor cells is the NPC or “lymphoepithe-
lioma” because histologically it shows an inflammation-like
microenvironment (Fig. 2 inset).25 Most of the infiltrating
lymphocytes in the tumors are CD3þ T cells with variable
CD4/CD8 composition, whereas B cells, monocytes, gran-
ulocytes, and other stromal cells are also present therein.
In contrast to their conventional antitumor functions, these
infiltrating immune cells are considered to facilitate NPC
progression in several ways.41e44 For example, inflamma-
tory cytokines produced by immune cells may serve as
growth factors for tumor cells, whereas cell-to-cell inter-
action through membrane-bound CD40 and CD40 ligand may
be another way whereby T cells promote survival of NPC
cells (Fig 2).31,45 LMP1 and Zta are two viral inducers of
chemokines in NPC cells, contributing to intensiveinfiltration of immune cells. Whilst Zta majorly upregulates
IL-8, LMP1 induces a broader spectrum of chemokines that
attract T cells.42,46 LMP1 and Zta may also contribute to the
establishment of an inflammation-like microenvironment
through upregulation of other cytokines (such as IL-6) and
transcription factors (such as NFkB or Egr-1).46e48 Distinct
from other head-and-neck carcinomas, NPC is also featured
by the tumor cells with the undifferentiated or poorly
differentiated phenotype. A subcategory of NPC with
spindle-shaped nuclei, suggesting that epithelial-to-
mesenchymal transition (EMT) exhibits a high metastatic
potential.49,50 The lymphoepithelioma-like carcinomas can
also emerge at various anatomic sites apart from naso-
pharynx, including salivary gland, lung, stomach, and
thymus.25 Interestingly, many lymphoepithelioma-type
cancers are also consistently associated with EBV infec-
tion, suggesting that EBV is a common etiologic factor
causing the histopathologic characteristics of nuclear
“undifferentiation” or EMT phenomenon. Reduction of
epithelial differentiation and induction of EMT change can
be caused by two EBV latent proteins, LMP1 and
LMP2A.49e51 Thus EBV plays a pivotal role in the patho-
morphogenesis of lymphoepitheliomas.Cellular stress in HL and NPC
Cellular stresses caused by extrinsic stimuli or intrinsic
events are important inducers of EBV reactivation or viral
oncogenes, explaining the high incidence of NPC in Hong
Kong Cantonese boat men.52,53 For example, oxidative
stress and DNA-damaging agents have been shown to induce
Figure 2 A unified model for EpsteineBarr virus (EBV)-associated nasopharyngeal carcinoma (NPC) pathogenesis. (Inset) The
tumor cells in nasopharyngeal carcinoma (NPC) show a syncytial growth pattern (lower right) with lymphoid infiltration (400).
Latent membrane protein 1 (LMP1) and Zta, two viral inducers of chemokines, contribute to inflammatory infiltration. Although Zta
majorly upregulates interleukin-8 (IL-8), LMP1 induces a broader spectrum of chemokines. LMP1 and Zta also contribute to an
inflammation-like microenvironment through upregulation of other cytokines (e.g., IL-6) and transcription factors [e.g., nuclear
factor kB (NFkB) or early growth response protein 1 (Egr-1)]. Induction of epithelial-mesenchymal transition (EMT) can be caused
by LMP1 and LMP2A. Besides, oxidative stress and DNA-damaging agents induce expression of EBV lytic genes. The cooperation of
EBV lytic infection and carcinogens synergistically increases oxidative stress and genomic instability. X-box-binding protein 1 (XBP-
1) is critical for LMP1 expression.
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tivation can also be triggered by some chemical carcinogens
that have been implicated as risk factors of EBV-associated
cancers such as NPC.55 The cooperation of EBV lytic infec-
tion and carcinogens synergistically increases oxidative
stress, genomic instability, and malignant phenotypes of
NPC cells,56 which is an integral link of environmental
factors to EBV-associated cancers. Besides the exogenous
stimuli, some endogenous stresses play regulatory roles in
EBV gene expression. ER stress frequently occurs in hyp-
oxia, inflammation, or solid tumors, resulting from accu-
mulation of misfolded proteins and perturbation of ER
homeostasis.57 ER stress induces EBV reactivation in B
lymphocytes, while upregulating the viral oncoprotein LMP1
in NPC cells. XBP-1, a transcription factor activated under
ER stress, is critical for expression of the EBV genes.58 By
contrast, LMP1 expression in HL cells can be induced by
some cytokines produced under inflammatory stress.
Cellular stresses can also be the downstream effects caused
by EBV proteins. For instance, an EBV nuclear protein
EBNA1 increases oxidative stress that enhances genomic
instability.59,60 Expression of LMP1 can induce ER stress in B
lymphocytes,61 which serves as a mechanism sustaining
LMP1 expression. In response to ER stress, cells may acti-
vate either cytoprotective pathways to recover from the
stress, or cytotoxic pathways to suicide under the stress.
Interestingly, LMP1-induced ER stress preferentially acti-
vates the cytoprotective pathways and attenuates the
cytotoxic pathways in HL cells, thus promoting survival oftumor cells.61 Moreover, our recent study also suggests that
EBV-LMP1 is one of the candidate molecules to induce the
multinuclear morphology of RS cells.62 Although the
mechanism of the LMP1-induced cytologic change has not
been fully confirmed, our study showed that LMP1 could
increase cytoplasmic localization of cyclin A, and the
cytoplasmic cyclin A promotes the multinucleation of HL
cells.62 Distinct from the cytoplasmic localization of cyclin
A in RS cells, the mononuclear Hodgkin cells consistently
express nuclear cyclin A. EBV-positive HL cells consistently
express large amounts of EBV LMP1 in the cytoplasm. The
accumulation of the viral oncoprotein LMP1 induces an ER
stress response.61 The RS cells of HL express strong ER
stress survival proteins XBP-1 and GRP78, but no expression
of the apoptotic ER stress proteins CHOP and ASK1.61
Although EBV may account for the characteristic histo-
pathologic features of HL, the same histopathologic fea-
tures also observed in EBV-negative HL suggest that an
unidentified pathogen or a similar mechanism may exist.
Therefore, cellular stresses seem to be coupled with
EBV-associated cancers in several ways. Initially the
stresses may dysregulate the “silent program” of EBV,
triggering aberrant EBV reactivation and oncogene expres-
sion. Subsequently the viral oncoproteins may induce
cellular stresses and adapt them for some events of onco-
genesis, especially for genomic instability and cell survival.
Furthermore, the feedback crosstalk between viral onco-
proteins and cellular stresses forms a driving force that
forwards host cells toward malignant phenotypes. Blockage
Virus and cancer 585of critical stress pathways is a possible approach to inhibit
both expression and effects of EBV oncoproteins. For
example, XBP-1 is not only an inducer of LMP1 but is also
involved in the survival pathways under ER stress, serving as
an attractive therapeutic target for EBV-associated
cancers.
HBV and HCC development
HCC is one of the most common malignancies around the
world, ranking the fifth in men and seventh in women, with
more than half of the cases occurring in Asia.16 The high
incidence of HCC in Asia largely reflects the prevalence of
chronic HBV infection in over 8% of the population.63,64 The
nationwide massive vaccination program has been
extremely successful in high incidence areas, such as
Taiwan, and the incidence of chronic HBV infection and
HBV-related HCC are largely reduced upon vaccination.65,66
However, there are more than 350 million individuals who
remain chronically infected by HBV and its late complica-
tions still account for approximately 1 million deaths/year
worldwide.65 In addition to antivirals, the development of
ideal agents for targeted therapy or chemoprevention is
urgently needed.
HBV-host interaction
The pathogenesis of HBV-mediated tumorigenesis can be
largely attributed to the life-long battle between the virus
and the host immune response. For chronic HBV carriers,
persistent HBV infection induces a weak adaptive immune
response with inefficient T-cell responses or immune
tolerance and therefore fails to eliminate HBV in the host.
Whilst incapable of complete viral clearance, the immune-
mediated damages and the subsequent regeneration in the
liver contribute significantly to the progression to liver
cirrhosis and HCC.67e70 In addition, viral factors including
insertional mutagenesis of the viral genome and the
expression of viral oncoproteins such as HBx and pre-S
mutant large surface proteins also play roles in HBV
tumorigenesis.27,28,69e72 Thus, it is likely that the interplay
between virus and host factors contributes synergistically
to activate oncogenic pathways that subsequently lead to
hepatocyte transformation.
HBV is a small DNA virus that has a partially double-
stranded circular genome consisting of only four open
reading frames, encoding the viral envelop/surface,
nucleocapsid, polymerase with a reverse transcriptase ac-
tivity, and X proteins. The surface gene is further divided
into three continued coding regions (pre-S1, pre-S2, and S
regions) with two internal start codons (pre-S2 and S ATG).
All three regions together encode the hepatitis B large
surface protein (LHBs), and this gene product is essential
for both virus assembly and infectivity.73,74 Among these
viral products, both X protein (HBx) and LHBs protein with
internal-deletions over the pre-S regions are considered
viral oncoproteins and tumor promoters. HBx and pre-S
mutants have been shown to exert their effects on the
cell cycle, cell growth, and apoptosis by interfering cellular
signaling pathways and gene transcriptions.75e78 Their roles
in tumorigenesis are further supported by the developmentof advanced liver diseases and HCC in transgenic
mice.27,79,80
HBx oncoprotein
HBx protein consists of 154 amino acids with a molecular
weight of 17 kDa.81 The multifunctional property of HBx
exerted in both in vitro and transgenic mice strongly argues
that HBx contributes directly or, at least, functions as a
cofactor in HBV tumorigenesis. HBx itself is a promising
gene transactivator that can activate a variety of viral and
cellular promoters and proto-oncogenes such as c-jun, c-
fos, and c-myc.82e84 In addition, HBx also activate tran-
scription factors such as NFkB, activator protein-1, and
activating transcription factor/cAMP-responsive element
binding transcription factor in the nucleus.85e87 In addition,
the expression of HBx in HepG2 cells renders resistance to
Fas-ligand-mediated apoptosis through activating the SAPK-
Janus kinase pathway.75 HBx also interacts directly with
p53 and thus represses p53-mediated gene transcription.77
Whilst it is known that HBx interferes with numerical signal
pathways in the in vitro model of cell culture, its clinical
and pathological relevance remains controversial. The
detection of HBx in the liver has been really challenging
due to the few antibodies available for immunohisto-
chemical staining.88 Thus, the role of HBx in HBV-mediated
hepatocarcinogenesis remains to be elucidated.
Pre-S mutants and ground glass hepatocytes
The large surface antigens with internal deletions over
either pre-S1 (pre-S1 mutant) or pre-S2 (pre-S2 mutant)
regions have been linked to advanced stages of liver disease
and HCC, indicating a contributing role of pre-S mutants in
HBV tumorigenesis.27,28,89e91 The presence of pre-S mu-
tants in serum has been reported to be a predictive marker
of advanced liver diseases and HCC.92 The pre-S mutants
were found to accumulate in ER of hepatocytes causing the
characteristic glassy or GGHs.27,29 There are two different
types of GGHs, the singular-distributed Type I GGHs con-
taining pre-S1 mutants and the clonally proliferated Type II
GGHs harboring pre-S2 mutants (Fig. 3).29 Notably, Type II
GGHs consistently cluster in groups and occur at the
advanced stages of virus replication and associated with
cirrhosis and HCC. Therefore, Type II GGHs are now
considered preneoplastic lesions in the liver.27,93
The accumulation of these pre-S mutants in ER has been
demonstrated to induce ER stress response due to the
accumulation of malfolded viral products in the ER.29,71 To
cope with HBV-induced ER stress, hepatocytes express
higher levels of ER chaperone proteins (GRP78 and GRP94),
cyclooxygenase-2 and vascular endothelial growth factor-A
to sustain their survival.28,94 The activation of ER stress
further promotes calcium release from the ER, leading to
the increase in oxidative stress intermediates and subse-
quent oxidative DNA damages.71 Based on the studies on
the biological nature of pre-S1 and pre-S2 mutants, we
consider it highly plausible that a stronger ER stress in Type
I GGHs may render cell death or growth arrest, however a
milder but sustained ER stress in Type II GGHs may confer
growth advantages by generating resistance to more
Figure 3 Histopathology of (A, B) Type I and (C, D) Type II ground glass hepatocytes (400). (A) Type I ground glass hepatocytes
(GGHs) are identified as hepatocytes with dense globular or (B) inclusion-like HBsAg staining. (A&B, lower field) Hepatoma cells
show no HBsAg expression. (B) Type I GGHs are usually scattered singly in the hepatic parenchyma. (C) Type II GGHs are identified
as (D) hepatocytes with HBsAg staining at the cell margin or periphery. (D) Type II GGHs are consistently arranged in a continuous
pattern and clusters in nodules.
586 K.-C. Chang et al.stringent conditions.27 Genomic instability is generally a
prerequisite for carcinogenesis in most cancer de-
velopments. Sustained ER stress induced by pre-S2 mutant
LHBs has been shown to induce strong oxidative DNA dam-
ages in the in vitro cultured cell lines, in type-II GGHs from
HCC patients and in pre-S2 mutant transgenic mice, sug-
gesting that pre-S2 LHBs itself is genotoxic.71,78,93 Our
recent investigation revealed that ER stress signal is
involved in the induction of cytoplasmic cyclin A, that
subsequently contributes to aberrant centrosome over-
duplication, and hence hepatocyte aneuploidy.95 The sus-
tained stress-induced DNA damage and chromosomal
abnormalities can explain the complex chromosomal
changes in HBV-related HCC.
The oncogenic potential of the pre-S2 mutant LHBs can
be attributed not only to the induction of a sustained ER
stress, but also to its function in gene transactivation. Pre-S2
mutant LHBs activates c-raf-1/Erk2 through the action of
protein kinase-C.96,97 In addition, the pre-S2 mutant LHBs
binds directly to c-Jun activation domain binding protein-1,
renders its nuclear translocation, and subsequently targets
p27Kip1 to proteasome-dependent degradation. This in turn
activates cyclin-dependent kinase-2 and results in hyper-
phosphorylation in retinoblastoma and hence the expression
of cyclin A and cell cycle progression.98 Additionally, mam-
malian target of rapamycin signals are activated by pre-S
mutant LHBs, which feedback suppress the synthesis of
surface antigens during the disease progression.99 Therefore,
both the gene transactivator function and ER stress induced
by pre-S2 mutant LHBs may act synergistically in promotinggenomic instability and lead further to hepatocyte trans-
formation. Accordingly, controlling the genotoxic damages
by HBV oncoproteins during chronic HBV infection may be a
useful approach for HCC chemoprevention in the future
(Fig. 4).Future perspectives on clinical treatment
The consistent activation of NFkB signals in NPC, HL, and
HCC raises the potential of targeting the NFkB pathway as
therapeutic and chemopreventive therapy.100e102 In EBV-
associated NPC and HL, NFkB signal is consistently acti-
vated and represents a major mechanism of virus-induced
tumorigenesis.26,85,103e107 Commercial NFkB inhibitors
may be used either alone or combined with chemothera-
peutic agents to suppress proinflammatory cytokine
release, to reduce the drug resistance, and to inhibit tumor
growth.108 The involvement of stress and inflammation
conditions in the development of virus-associated cancers
provides the strategy to adopt chemopreventive agents or
natural products to prevent or reduce the tumor formation
in high risk individuals. Current studies suggest that natural
products that exhibit pleiotropic effects and few side ef-
fects are ideal chemopreventive agents. Among which, the
agonists of peroxisome proliferators activated receptors
(PPAR) represent the most promising candidates.109,110 Most
of the currently studied chemopreventive agents such as
resveratrol, curcumin, and unsaturated fatty acids in fish
oils, vegetables, and fruits exhibited PPAR agonistic
Figure 4 Diagram to illustrate the disease progression from chronic HBV infection, cirrhosis, dysplastic hepatocytes to hepa-
tocellular carcinoma. Ground glass hepatocytes (GGHs), especially Type II GGHs, are now recognized as preneoplastic lesions and
show oxidative stress, DNA damage, and genomic instability. Specific signals include vascular endothelial growth factors (VEGFs),
nuclear factor kB (NFkB), and serine/threonine-protein kinase/mammalian target of rapamycin (Akt/mTOR), which are activated
sequentially. The stagewise activation of signals from inflammation and endoplasmic reticulum (ER) stress provides targets for
chemoprevention at the early stage of tumorigenesis.
Virus and cancer 587activities.111,112 Clinical trials to apply these natural prod-
ucts in chemoprevention for virus-associated human can-
cers remain to be carefully designed in high-risk patients to
avoid tumor recurrence.113 The safety of agents in cancer
chemoprevention strategy is the major concern and the risk
benefit ratio of the agents needs to be carefully evaluated.
The assay of modulation of PPARɣ prior to and after inter-
vention would be useful biomarkers for interpretation of
such trials. Future insight into the pathobiology and mo-
lecular mechanisms of virus-associated cancers and the role
of host-virus interaction in tumor development and pro-
gression will improve the clinical treatment.
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